Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
MA Giorgi, C Caroli, ND Giglio, P Micone… - Health Economics …, 2015 - Springer
Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke
and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and …
and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and …
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised …
Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation
Background—In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and …
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and …
Comparative effectiveness and safety of apixaban and vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation treated in routine German practice
CI Coleman, WF Peacock, M Antz - Heart, Lung and Circulation, 2018 - Elsevier
Background Scarce data comparing real-world outcomes between apixaban and vitamin K
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to …
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to …
[HTML][HTML] Apixaban versus warfarin in patients with atrial fibrillation
CB Granger, JH Alexander, JJV McMurray… - … England Journal of …, 2011 - Mass Medical Soc
Background Vitamin K antagonists are highly effective in preventing stroke in patients with
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa …
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa …
Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?—a systematic review
TAC de Vries, J Hirsh, K Xu, I Mallick… - Thrombosis and …, 2020 - thieme-connect.com
Background Recent reports suggest an important contribution from frequent off-label use of
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
S Halvorsen, D Atar, H Yang… - European heart …, 2014 - academic.oup.com
Aims The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the
ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death …
ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death …
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation
AR Harrington, EP Armstrong, PE Nolan Jr, DC Malone - Stroke, 2013 - Am Heart Assoc
Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial
Aims It is uncertain whether the benefit from apixaban varies by type and duration of atrial
fibrillation (AF). Methods and results A total of 18 201 patients with AF [2786 (15.3%) with …
fibrillation (AF). Methods and results A total of 18 201 patients with AF [2786 (15.3%) with …
Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis
BJR Buckley, DA Lane, P Calvert, J Zhang… - Journal of clinical …, 2022 - mdpi.com
Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …